Scholarlink

Purpose <p>Patients with liver metastases from gallbladder carcinoma have limited treatment options. This retrospective multicenter study evaluated overall survival, tumor control and safety after transarterial radioembolization in this rare patient group.</p> Materials and methods <p>Patients with histologically confirmed gallbladder carcinoma and liver-dominant metastatic disease treated with yttrium-90 or holmium-166 radioembolization at five tertiary centres were retrospectively identified. Baseline clinical and imaging data, details of the radioembolization procedure and follow-up imaging were collected. Tumor response was assessed locally using RECIST 1.1. Overall survival was analysed descriptively using Kaplan–Meier curves.</p> Results <p>Sixteen patients (9 women, mean age 65.7 ± 5.5 years) were included; 93.8% had received prior systemic chemotherapy and 75.0% had extrahepatic metastases. At approximately 3 months, hepatic disease control was achieved in 81.8% (9/11) of patients with available imaging, whereas global disease control was 36.4% (4/11). Median overall survival was 7.1 months (95% confidence interval 1.7–12.3). The median time to hepatic progression was 115 days and the median time to global progression was 112 days. Procedure-related complications were limited to one coil dislocation, one contrast reaction and one liver abscess.</p> Conclusion <p>Radioembolization was feasible and well tolerated in patients with liver-dominant metastases from gallbladder carcinoma and provided intrahepatic disease control in a heavily pretreated population. Given the small sample size, these exploratory findings require confirmation in prospective studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-life experience in the treatment of gallbladder carcinoma by transarterial radioembolization: a multicenter retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月25日

查看全文
  • Thomas Dertnig,
  • Roman Kloeckner,
  • Lukas Mueller,
  • Timo Alexander Auer,
  • Arthur J. A. T. Braat,
  • Malte Maria Sieren,
  • Ulf Neumann,
  • Stefan Kasper,
  • Leonie S. Jochheim,
  • Benedikt M. Schaarschmidt

摘要

Purpose

Patients with liver metastases from gallbladder carcinoma have limited treatment options. This retrospective multicenter study evaluated overall survival, tumor control and safety after transarterial radioembolization in this rare patient group.

Materials and methods

Patients with histologically confirmed gallbladder carcinoma and liver-dominant metastatic disease treated with yttrium-90 or holmium-166 radioembolization at five tertiary centres were retrospectively identified. Baseline clinical and imaging data, details of the radioembolization procedure and follow-up imaging were collected. Tumor response was assessed locally using RECIST 1.1. Overall survival was analysed descriptively using Kaplan–Meier curves.

Results

Sixteen patients (9 women, mean age 65.7 ± 5.5 years) were included; 93.8% had received prior systemic chemotherapy and 75.0% had extrahepatic metastases. At approximately 3 months, hepatic disease control was achieved in 81.8% (9/11) of patients with available imaging, whereas global disease control was 36.4% (4/11). Median overall survival was 7.1 months (95% confidence interval 1.7–12.3). The median time to hepatic progression was 115 days and the median time to global progression was 112 days. Procedure-related complications were limited to one coil dislocation, one contrast reaction and one liver abscess.

Conclusion

Radioembolization was feasible and well tolerated in patients with liver-dominant metastases from gallbladder carcinoma and provided intrahepatic disease control in a heavily pretreated population. Given the small sample size, these exploratory findings require confirmation in prospective studies.